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Abstract Myocardial perfusion scintigraphy is a valuable
clinical tool for assessing coronary blood flow deficits in
patients. We recently synthesized a new iodinated com-
pound (123I-CMICE-013) based on rotenone and showed
that it has excellent performance as a radiotracer for
myocardial perfusion imaging. Here, we describe the cel-
lular toxicity and subacute toxicity of CMICE-013 in rats.
Cultured hepatocytes displayed sensitivity to rotenone but
not CMICE-013 at equimolar concentrations. Following
i.v. injection of CMICE-013 for 14 days, body weight,
ambulation, behavior, grooming, guarding (abdominal,
muscular), pale conjunctivae, and food intake were
observed. Biochemical, hematological, and histopatholo-
gical changes in tissues (heart, liver, kidney, spleen, lung,
and brain) and echocardiography at pre- and post-dosing
were also examined. All animals responded well to the
daily injections of CMICE-013 and showed no mortality or
adverse reactions with respect to the parameters above.
Subacute i.v. injections at high- (5 lg/kg) and low (1 lg/
kg)-dose levels did not result in any significant changes to
either biochemical or hematological parameters and no
detectable changes in histopathology compared to the
vehicle or untreated animals. Echocardiographic analyses,
including the measurements of cardiac function and anat-
omy (wall thickness, left atrial size, and left ventricular
mass), were not different at pre- versus post-dose measures
and were not different compared to the vehicle or untreated
animals. Our observations in small animals reveal that
CMICE-013 induces minimal toxicity when delivered
intravenously for 14 days.
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Myocardium  Perfusion  Radiotracer  SPECT molecular
imaging
Introduction
Coronary artery disease is the major cause of early mor-
bidity and mortality in North America and worldwide. The
early detection of heart disease is of paramount importance
in risk stratification for heart patients. As such, myocardial
perfusion scintigraphy has become a favored tool for the
noninvasive detection of obstructive coronary artery dis-
ease in patients with presumptive perfusion deficit. Thal-
lium-201 was the first radionuclide used universally for
myocardial perfusion scintigraphy [23, 26]. The medical
community has since adopted numerous agents for the
noninvasive assessment of myocardial perfusion. Cur-
rently, the more frequently used agents are the Techne-
tium-99 m compounds sestamibi and tetrofosmin.
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Differential uptake of these tracers in cardiomyocytes as
determined by blood flow permits the discrimination
between normal and ischemic myocardium.
Accumulation of 201Thallium-chloride, 99mTc-sestamibi,
and 99mTc-tetrofosmin in the cell is related to membrane
potential [4, 9, 19, 25]. Localization of these tracers
appears to be determined by regional intracellular ionic
charge. The negative mitochondrial membrane potential
facilitates the sequestration of sestamibi and tetrofosmin to
the mitochondria, whereas thallium, a K? analog, resides
predominantly in the cytosolic compartment. We recently
designed a new radiotracer CMICE-013, which is a rote-
none analog with modifications at the 60 and 70 carbons.
With CMICE-013, rotenone is iodinated at the 70 carbon. A
hydroxyl group is added to the 60 carbon, and the 70 double
bond is reduced to a single bond. This renders CMICE-013
more hydrophilic than rotenone. CMICE-013 is suitable for
SPECT myocardial perfusion scintigraphy and was shown




chromen-6-one] is a naturally occurring toxin that is
structurally related to the isoflavone family of compounds.
Rotenone is derived from the roots of select tropical plants
of the Leguminosae family, namely cube or barbasco
(Lonchocarpus utilis and L. urucu), derris (Derris ellipti-
ca), rosewood (Tephrosia spp.), and Rabbit’s pea (Dal-
bergia paniculata). Root extracts from these plants have
been used for centuries as a pesticide in South America and
Southeast Asia [17].
Rotenone, as with many other pesticides, functions at
the level of mitochondrial respiration by blocking the
oxidation of reduced nicotinamide adenine dinucleotide
(NADH) to NAD. Recent evidence suggests that these
compounds bind within a cavity situated at the interface of
49-kDa and PSST subunits of mitochondrial complex I [29,
32]. Interestingly, the region of binding is specific despite
the structural diversity among complex I-inhibiting pesti-
cides [29]. The loss of NAD results in a failure to oxidize
key substrates of the tricarboxylic acid cycle. Additional
effects of rotenone include alterations to fatty acid
metabolism and aerobic oxidation [8, 13, 15, 35], and
excessive doses of rotenone can cause neurotoxicity
resulting in Parkinson’s-like phenotypes [7, 27, 28].
Given the high affinity of rotenone for mitochondrial
complex I and that cardiomyocytes are highly enriched
with mitochondria, we have designed a series of rotenone
derivates for use in myocardial perfusion scintigraphy. In
particular, a candidate derivative CMICE-013 was recently
employed in a series of animal studies. This compound had
high specificity for the myocardium, thus signifying its
potential as a perfusion tracer for assessing coronary artery
disease (CAD) [33]. In view of the potent pesticidal
mechanism of rotenone, we report here a comprehensive
toxicological evaluation of the rotenone derivative




In previous studies where CMICE-013 was evaluated as a
myocardial perfusion tracer, radiolabeled CMICE-013, i.e.,
123I-CMICE-013, was employed. In the present study, we
used the non-radioactive analog 127I-CMICE-013. The
preparation and characterization of 127I-CMICE-013
(herein referred to as CMICE-013) was conducted under
sterile and aseptic conditions as described [33]. Briefly,
rotenone in trifluoroacetic acid (TFA) was mixed with NaI
in 0.1 M NaOH. A 15 mg/mL solution of iodogen (1,3,4,6-
tetrachloro-3a,6a-diphenylglucoluril) in TFA was added
drop wise with stirring. The reaction mixture was heated to
60 C with constant mixing for 45 min and then concen-
trated with a rotary evaporator (Buch, R-210). Milli-Q
water and dichloromethane were added sequentially to the
mixture to facilitate a liquid–liquid extraction. The organic
phase was collected and dried over sodium sulfate. Fol-
lowing evaporation, the crude product was purified on a
preparative reverse-phase column (Phenomenex Luna
C18(2)) and eluted with Milli-Q water and 95 % ethanol.
The purified product was collected and evaporated to
complete dryness.
The maximum formulated dose of CMICE-013 suitable
for clinical use was 5.0 lg/kg in 5 % ethanol/10 mM
sodium acetate (pH 5). As such, a low and high dose, 1.0
and 5.0 lg/kg, respectively, was prepared for animal
studies and their concentrations were determined by HPLC.
The final low- and high-dose CMICE-013 products were
dispensed into crimped vials and stored for a single thaw
use at -80 C.
Serum stability measurements
Approximately 0.9 lg/L of CMICE-013 or rotenone in 5 %
ethanol was added to an equal volume of rat serum or PBS
and incubated at 37 C for various times with mixing at
400 rpm. An equal volume of 95 % ethanol (1:1:1 com-
pound:serum/PBS:ethanol) was added and the reaction was
centrifuged at 4,000 rpm for 5 min at room temperature.
An aliquot of each sample was filtered through a 10 K
MWCO centrifugal filter (Pall, Port Washington, NY) at
14,000 9 g for 25–30 min at 12 C. The filtrate was ana-
lyzed by reverse-phase HPLC (Phenomenex Luna C18(2),
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and the UV trace at 290 nm was integrated to examine the
signal peak for either CMICE-013 or rotenone. The per-
centage peak area was calculated using Empower 2 soft-
ware (waters) and plotted for each time point.
In Vitro Hepatotoxicity Assays
Normal human hepatocytes (THLE-3, ATCC, Manassas,
VA) were maintained in BEGM media with supplements
from the BEGM Bullet Kit (CC3170, Lonza/Clonetics,
Walkersville, MD) excluding gentamycin/amphotericin
and epinephrine and including additional 5 ng/mL of epi-
dermal growth factor (Life Technologies, Burlington, ON),
phosphoethanolamine (70 ng/mL, Sigma-Aldrich, St.
Louis, MO), and fetal bovine serum (10 %, Life Technol-
ogies). Cells were plated onto 96-well plates precoated
with 0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen
type I, and 0.01 mg/mL BSA (Sigma-Aldrich). Cells were
incubated for 24 h with either rotenone, CMICE-013, or
vehicle (5 % ethanol/10 mM sodium acetate), and cell
viability was determined using a colorimetric Cell Cyto-
toxicity Assay Kit (Abcam, Cambridge, MA) by monitor-
ing the change in absorbance at 570 and 605 nm on a
BioTek Synergy HT plate reader.
LDH activity was determined using an LDH Cyto-
toxicity Assay Kit (Pierce, Rockford, IL). Approxi-
mately 2 9 104 THLE-3 cells were seeded onto each
well of a 96-well clear tissue culture plate precoated as
above. Cells were allowed to adhere overnight and then
treated with varying concentrations of either rotenone,
CMICE-013, or vehicle for 6 h. The assay was then
conducted as per the manufacturer’s instructions, and
the absorbance at 490 and 680 nm was determined
(BioTek Synergy HT).
Mitochondrial membrane potential was determined
using the TMRE Mitochondrial Membrane Potential Assay
Kit (Abcam). THLE-3 cells at approximately 2 9 104
cells/well were seeded onto a black walled, clear bottom
96-well culture plate precoated as above. Cells were
allowed to adhere overnight and then treated with varying
concentrations of either rotenone, CMICE-013, or vehicle
for 6 h. TMRE-based mitochondrial accumulation was
measured on a BioTek Synergy HT plate reader in fluo-
rescence mode.
Animals
Male and female Sprague–Dawley rats (Charles River,
St-Constant, PQ) at pre-dose weights of approximately
250–300 g (female) and 375–430 g (male) were acclimated
for at least 1 week prior to experimentation. Animals were
housed in groups of two at 20–24 C and 30–50 % rh under
a 12-h diurnal light cycle and were provided food and
water ad libitum (Harlan Teklad Certified Global Rodent
Diet, Montreal, PQ). All animal procedures were approved
by the University of Ottawa Animal Care Committee and
in accordance with the guidelines and regulations stated by
the Canadian Council on Animal care.
Animal Assignments and Dosing
Using an operator-blinded design, animals were ran-
domly assigned to saline, vehicle (5 % ethanol/10 mM
sodium acetate), 1 lg/kg CMICE-013 or 5.0 lg/kg
CMICE-013 (N = 8 for all groups). A single daily dose
was administered intravenously via the tail vein using
alternate left and right sides of the tail on each day of
injection in order to minimize scaring and irritation at
the injection site.
Cage-side observations including weight, ambulation,
behavior (bright, alert, responsive), signs of lethargy, ruf-
fled fur, lack of grooming, guarding (abdominal, muscular),
pale conjunctivae, and decreased food intake were moni-
tored daily throughout the study.
Echocardiography
Echocardiography was assessed prior to dosing (baseline)
and again after day 14 for each animal. Animals were
sedated under 2–3 % isofluorane for a maximum of
30–45 min during the echocardiographic acquisition.
Measurements were taken using Vevo 770 software
(VisualSonics Inc., Amsterdam) and included parasternal
long-axis assessment (B-mode) and short-axis measures
(M-mode) of left ventricular diastolic and systolic volumes,
stroke volume, cardiac output, wall thickness, ejection
fraction, and fractional shortening. Left atrial size was
measured in M-mode and averaged over five views.
Necropsy and Histopathology
Following the final ultrasound scan, animals were eutha-
nized by CO2 asphyxiation and a necroscopic examination
was performed on each animal, which included a gross
examination and macroscopic organ assessment with the
preservation of blood, heart, liver, lung, kidney, spleen, and
brain. Tissue samples were immediately preserved in 10 %
buffered formalin. Blood smears, EDTA blood, and serum
were processed and analyzed for biochemistry and com-
plete blood count (Animal Health Laboratory, University
of Guelph, Guelph ON). Following a minimum of 48-h
fixation, the tissues were embedded in paraffin and sections
were cut at 7.0 lm and stained with hematoxylin and eosin
(H&E) to examine cellular morphology and intracellular
structures.
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Statistical Evaluations
Analyses were completed using a two-way analysis of
variance with a Bonferroni post hoc comparison of means.
The complete blood count and blood biochemistry results
are shown per gender and compared in a similar manner.
Echocardiography results were analyzed using a paired
two-way analysis of variance comparing gender at pre- and
post-treatment across treatment groups.
Results
Compound Stability
Rotenone was stable in PBS but showed significant
breakdown in rat serum at 37 C. After 30 min in serum,
approximately 75 % of rotenone remained intact relative to
rotenone in PBS (p \ 0.001). This reduced to approxi-
mately 35 % after 240 min (p \ 0.0001). In contrast,
CMICE-013 had weak stability in PBS and extremely poor
stability in rat serum (p \ 0.0001). By as early as 15 min,
almost half of the CMICE-013 was degraded relative to
pre-incubation. After 240 min in serum at 37 C, less than
10 % of CMICE-013 was intact. Despite the weak stability
of both compounds, rotenone was more stable after
240 min relative to CMICE-013 (p \ 0.0001).
In Vitro Cytotoxicity
THLE-3 cells demonstrated sensitivity to increasing con-
centrations of rotenone, whereas minimal cytotoxicity was
observed at similar concentrations of CMICE-013.
Approximately 85–90 % of cells remained viable with up
to a maximal concentration of 2.5 lM CMICE-013.
whereas a 50 % viability was found after treatment with
1.0 lM rotenone (p \ 0.0001) (Fig. 1).
Serum LDH activity increased with elevated concen-
trations of either rotenone or CMICE-013 (p \ 0.001). At
1.5 lM CMICE-013, no further changes in LDH activity
were found. Overall, rotenone induced higher LDH activity
at concentrations above 0.5 lM (p \ 0.01).
The accumulation of tetramethylrhodamine ethyl ester
(TMRE) in the mitochondria was used to assess mito-
chondrial membrane potential. Although there was a sig-
nificant effect of concentration on mitochondrial
membrane potential (p \ 0.001), the effect of either rote-
none or CMICE-013 was not different.
bFig. 1 Stability and cellular toxicity of rotenone and CMICE-013.
a Rotenone and CMICE-013 were incubated in PBS or rat serum and
assessed by reverse-phase HPLC. Shown are the percent peak areas
based on the HPLC chromatogram for each sample at the respective
time point. Values are expressed as the mean ± SEM from 3
independent repetitions per time point for each sample. b THLE-3
cells were incubated with either rotenone or CMICE-013 at varying
concentrations for 24 h. Viability was expressed as a percentage of
the total cells in the vehicle-treated condition. Values are mean ±
SEM from 5 independent assays for each compound. c Lactate
dehydrogenase activity in serum following a 6-h incubation of THLE-
3 cells with rotenone or CMICE-013. Values are mean ± SEM from
4 independent assays for each compound. d Mitochondrial membrane
potential as indicated by the sequestration of TMRE by active
mitochondria after 6 h of incubation with either rotenone or CMICE-
013 was measured by fluorescence spectroscopy. Values are
mean ± SEM from 3 independent assays for each compound
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Cage-Side Observations and Animal Weight
Rats administered with 1 or 5 lg/kg CMICE-013 failed to
show signs of abnormal behavior or discomfort during and
several hours after administration. Animals displayed
normal ambulation and remained alert and responsive
immediately after injection. Throughout the 14-day period,
animals did not show signs of guarding and appeared to
maintain normal grooming and eating behaviors. Mortality
was not observed during the 14-day treatment with
CMICE-013 in either sex.
Both male and female rats across all treatment groups
continually gained body weight throughout the duration of
the study (Fig. 2). Despite the positive total weight gain
over 14 days, animals that received saline had significantly
lower body weights relative to the vehicle and treatment
groups (p \ 0.001 for both males and females).
Hematological Analyses
Hematological indices such as red and white blood cell
number, hematocrit, mean corpuscular volume, mean
platelet volume, total serum protein, lymphocyte, and
monocyte counts were not significantly different from
control and vehicle with CMICE-013 treated rats after
14 days (Table 1).
Biochemical Analyses
After 14 days of treatment, the standard biochemical
parameters including total protein, albumin, globulin, urea,
glucose, cholesterol, and total bilirubin were not different
among the treatment groups. A slight increase in blood
glucose concentration appeared with elevated CMICE-013
concentrations for both male and female rats but was not
significant (p \ 0.05) (Table 2). Key markers of renal and
hepatic function including alkaline phosphatase, alanine
aminotransferase, aspartate aminotransferase, and gamma-
glutamyl transaminase remained unchanged after 14 days
of CMICE-013 treatment (Table 2).
Organ Weights and Histology
Gross examination of isolated heart, liver, kidney, and
spleen did not reveal any abnormalities or differences in
their mean weights. Organ weights expressed relative to
animal body weight were compared in order to normalize
for variances in size due to gender (Table 3). Overall,
histological examination using H&E staining did not reveal
differences in organs between treatment groups. The
intestinal layers of the large intestine appear intact and
unchanged between treatment groups (Fig. 3). Examination
of the spleen across treatments shows that the connective
tissue appears dense with normal lymphatic nodules.
Hepatocytes have normal architecture and show granulated
cytoplasms. In addition, the kidneys display regular tubules
and glomeruli with normal architecture across all treatment
groups. The intramural coronary arteries within the lung
displayed some evidence of edema in all treatment groups
but this was not a predominant finding overall. The myo-
cardium of the left ventricle displayed regular striated
myocytes with nuclei that were normal in appearance.
Neuronal degeneration or cytoplasmic inclusions in
coronal sections of the substantia nigra pars compacta after
a 14-day treatment with CMICE-013 in rats was not evi-
dent. Moreover, immunohistochemical analyses of coronal
cross sections were negative for the Parkinson’s disease
markers a-synuclein and tau (data not shown). Indeed, the
absence of a Parkinson’s-like phenotype is a favorable
finding for the purposes of a diagnostic tracer to assess
myocardial perfusion.
Echocardiography
Echocardiography compared at pre-dosing and after
14 days of treatment did not reveal any significant changes
in cardiac function or anatomy. As expected, gender dif-
ferences were noted in some variables where males showed
elevated systolic and diastolic volumes, stroke volume, and
cardiac output (Fig. 4). In addition, males also had higher
Fig. 2 Effect of CMICE-013 on animal body weight. Body weight
was measured daily for both male (a) and female (b) rats. Values are
mean ± SEM of 8 rats in each group
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LV mass and left atrial size relative to females (Fig. 5).
The observed differences in male rats are likely due to
their larger body mass; however, differences between pre-
and post-dose measures within gender were not evident.
Discussion
Myocardial radio-perfusion tracers are able to provide
valuable clinical information for diagnosing perfusion
deficits. The predominant mechanism of action for the
currently available perfusion radiotracers is through cyto-
plasmic or mitochondrial accumulation following mem-
brane transport. Although this mode of cellular uptake is
sufficient, it is often not as effective as molecules that have
direct binding or high-affinity interaction with cellular
components. 99mTc-based perfusion compounds are known
to associate with the mitochondria; however, it is not yet
clear whether they bind specifically or are merely held
within the mitochondria. Given the high concentration of
mitochondria within the myocardium, the binding of
rotenone to mitochondrial complex I allows a more potent
and specific mechanism for myocardial perfusion tracers.
In a previous study, we synthesized a derivative of rote-
none, 60-hydroxy-70-iodo-rotenone (CMICE-013), and
showed that it had excellent myocardial perfusion char-
acteristics and favorable biodistribution in vivo [33]. Here,
we demonstrate that CMICE-013 has an apparently benign
toxicological profile in rats when delivered intravenously
for 14 consecutive days.
Modification of the 60 and 70 positions of rotenone
significantly limited the stability of CMICE-013. Serum
stability in vitro is likely reflective of stability in vivo,
although this needs to be confirmed through further ana-
lysis of rodent serum following injection of CMICE-013.
Nonetheless, the limited degree of CMICE-013 stability
may be the primary mechanism for the lack of toxicity that
was observed both in cultured cells and in animals.
Interestingly, despite the unstable nature of CMICE-013
in vitro, this compound performs exceptionally well as a
perfusion tracer and demonstrates sufficient accumulation
in the rodent myocardium [33].
In this study, we used Thle-3 cells as a hepatocyte test
model for assessing the cytotoxicity of CMICE-013. Thle-
3 hepatocytes are a normal human immortalized liver cell
line that have similar morphological, genetic, and bio-
chemical features of primary human hepatocytes [24].
Importantly, these cells are able to metabolize compounds
in a similar manner to primary human hepatocytes. The
lack of CMICE-013 toxicity relative to rotenone in cul-
tured hepatocytes may be explained by the highly unstable
nature of CMICE-013 in serum. Further investigation both
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Typically, subacute toxicity studies are conducted using
a range of doses both above and below the suggested
human dose. In the present study, rats were administered
an intravenous maximal dose of 5 lg/kg daily for 14 days
with CMICE-013. CMICE-013 was designed to be a
molecular imaging radiotracer with a projected clinical
dose of 0.1 lg/kg delivered as a single intravenous injec-
tion, which is well below the dose levels used in the
present study. CMICE-013 shares similar physical prop-
erties with rotenone in that it is soluble in ethanol at 2 g/L
@ 20 C [17]. In the clinical formulation, CMICE-013 is
not soluble beyond 7.3 lg/mL. Given such a low antici-
pated human dose, we chose to explore the toxicity of this
tracer when administered at a dose of 1.0 lg/kg and at the
maximum formulatable dose of 5.0 lg/kg.
Over a 14-day period, CMICE-013 at either the low- or
high-dose level did not impede the weight gain in either
male or female rats. Male rats injected with saline had
lower weights than males in the other experimental groups.
However, despite using a random group assignment pro-
tocol, rats that received saline also had lower baseline
weights prior to injection. This suggests that the differ-
ences in weight are not likely attributable to the test
compound or the excipients. In addition, all animals were
observed to be alert and responsive throughout the dosing
period with normal ambulation and gait and did not display
signs of guarding or deficient grooming, further signifying
that at the doses administered intravenously, CMICE-013
did not adversely affect the health of the animals over a
14-day period.
Changes in the hematological system of animals are
relatively consistent with human toxicity when studies are
conducted for 1 month or less [21]. In our 14-day treat-
ment trial, changes in hematological parameters such as
hematocrit, hemoglobin concentration, red and white blood
cell number, red cell distribution width, and mean platelet
volume were not observed between control and CMICE-
013-injected animals. This suggests that the compound did
not affect existing red cells and did not interfere with
erythropoiesis and platelet formation. The lack of changes
in serum protein and lymphocyte and monocyte numbers
following CMICE-013 dosing further supports this
conclusion.
Biochemical parameters remained unchanged in both
males and females following CMICE-013 administration
for 14 days. The slight but nonsignificant increase in blood
glucose with treatment may arise from the 5 % ethanol
excipient in the formulation. Importantly, the serum levels
of alanine transaminase (ALT), aspartate transaminase
(AST), alkaline phosphatase (ALP), and gamma-glutamyl
transferase (GGT) were not affected by CMICE-013 dos-
ing. ALT, AST, ALP, and GGT are key markers of hep-
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Serum ALT is considered the gold standard indicator of
hepatotoxic effects but is often assessed in conjunction with
other makers [2, 22]. ALT has two isoforms ALT1 and
ALT2 that display differential tissue expression, which may
explain the need to assess ALT in relation to other bio-
markers of toxicity [16, 37]. Within liver cells, both ALT
and AST are localized to the cytoplasm and the mitochon-
dria, however, ALT is found within the periportal region
while AST is ubiquitously expressed. The liver has the
highest expression of ALT1 but lower levels are also found
in skeletal muscle and heart. ALT2 is restricted to skeletal
muscle and heart [16]. In comparison, AST has lower levels
of expression in the liver and is found more abundantly in
skeletal muscle, heart, brain, and kidney. Thus, AST can
originate from damaged myocytes as well as hepatocytes,
and the ratio of AST:ALT can reveal differences in liver
Fig. 3 Histopathological analysis of select tissues after 14 days of
subacute i.v. administration of CMICE-013. Histopathological micro-
graphs of large intestine (a–d), spleen (e–h), liver (i–l), kidney (m–p),
lung (q–t), and heart (u–x). Figures are representative of micrographs
from tissue of three animals for each condition. Scale bar 100 lm
178 Cardiovasc Toxicol (2014) 14:170–182
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damage relative to other organs [3, 22]. In our studies,
AST:ALT was unchanged across treatments for both males
and females (p \ 0.05). These results would suggest that in
addition to the liver, CMICE-013 did not induce cytotox-
icity in either skeletal- or cardiomyocytes, despite its high
affinity for mitochondria and mitochondria rich tissues.
Rotenone is commonly used to model Parkinson’s dis-
ease in rats [6, 12, 20]. These studies typically require large
systemic doses of rotenone ([ 2–3 mg/kg/day) for exces-
sive periods ([ 3 weeks) [5, 7]. Bilateral lesions in the
striatum with neuronal loss were found after 1 week of
rotenone delivery in rats. However, this phenotype
emerged using intravenous infusion of rotenone at con-
centrations of 10–18 mg/kg per day [11]. Nigrostriatal
dopmainergic loss was found after intravenous and sub-
cutaneous infusion of 2–3 mg/kg per day of rotenone in
rats; however, neurodegeneration did not appear until at
least 3 weeks [5, 30]. Moderate doses of rotenone resulted
in neurodegeneration of the nigrostriatal dopaminergic
pathway after 1 week; however, a chronic sustained
delivery via osmotic minipumps was required to bring
about this effect [10]. In contrast, degenerated dopami-
nergic neurons were observed in rats given daily intra-
peritoneal injections of rotenone at 1.5 and 2.5 mg/kg for
2 months [1]. Clearly, studies that use rotenone to model
PD in rodents require significant doses over prolonged
periods. Although CMICE-013 is structurally different than
rotenone and has attenuated cytotoxicity in cultured cells, it
has similar mechanistic properties, i.e., affinity for mito-
chondrial complex I. Nonetheless, the most obvious
explanation for the lack of a PD-like phenotype in our
studies is likely attributable to the low doses of CMICE-
013 relative to other studies that use rotenone.
Although echocardiography is not a widespread
approach in toxicological profiling, it has been used on
several occasions to investigate drug-induced cardiotoxic-
ity and is gaining recognition as a reliable tool for assessing
the pharmacological effect of drugs [14, 36]. The
Fig. 4 Echocardiography-based
functional assessment at pre-
dose and after 14 days of
subacute dosing of CMICE-013.
a Diastolic volume, b systolic
volume, c stroke volume,
d fractional shortening,
e cardiac output, f ejection
fraction. Values are
mean ± SEM of 8 rats in each
group
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mechanistic action of rotenone and CMICE-013 may
facilitate the perturbation of cardiomyocyte metabolic
activity and ultimately affect contractility. However, the
echocardiographic analyses did not reveal such an effect.
Measurements at baseline and after 14 days of CMICE-013
treatment did not show differences in stroke volume, car-
diac output, ejection fraction, and percent fractional
shortening, strongly suggesting that hemodynamic function
remained unchanged. Furthermore, over a 14-day period,
CMICE-013 was unable to induce anatomic changes in the
myocardium with respect to wall thickness, left ventricular
mass, and left atrial size. These results were also confirmed
at the time of necropsy through gross morphological
examination and with histological analyses of the myo-
cardium. Conceivably, anatomic changes may require a
longer period to manifest. Anatomic changes in the heart
following myocardial ischemia/infarction typically appear
after 3–4 weeks, and therefore, a longer observation period
may be necessary to determine the phenotypic effects on
the myocardium with chronic CMICE-013 administration.
Our studies suggest that CMICE-013 is a less toxic variant
of rotenone. This may be explained by its attenuated stability
in serum but may also be attributed to structural modifica-
tions, despite having similar avidity as rotenone for MC-1.
Fig. 5 Echocardiography-based anatomical assessment at pre-dose
and after 14 days of subacute dosing of CMICE-013. a Heart rate,
b wall thickness, c left ventricle mass, d left atrial size. Values are
mean ± SEM of 8 rats in each group. Representative M-mode
sonograms of the left ventricle from a male rat at pre- (e) and 14-day
post-dose (f) and female at pre- (g) and 14-day post-dose (h) with
5.0 lg/kg/day of CMICE-013. The calculated left ventricular end-
diastolic volume (EDV) and left ventricular end-systolic volume
(ESV) based on the wall motion depth tracing is shown for each
image
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Although rotenone toxicity is known to exert effects via the
inhibition of mitochondrial activity, cytotoxicity is not
exclusively limited to the inhibition of MC-1. In neuro-
blastoma cells, rotenone induced cytotoxicity through both
metabolic perturbation and apoptosis [18]. Rotenone also
induced cytotoxicity through the activation of apoptotic
signaling pathways [31, 34]. In murine microglia, rotenone
induced cytotoxicity through NFjB-associated signaling
including the release of TNFa and IL-1b, elevated TNFa and
IL-1b mRNA, and increased the phosphorylation of IjB,
ERK, JNK, and p38 MAPK [38]. Clearly, rotenone can exert
toxicity through mechanisms that are indirect of mitochon-
drial complex-1 inhibition. Given the differences observed
with CMICE-013 relative to rotenone, a comprehensive
study examining the structure–activity relationship is war-
ranted within the context of cellular toxicity.
In summary, this study describes the toxicological out-
come following intravenous administration of the rotenone
derivative CMICE-013 at low (1.0 lg/kg) and high
(5.0 lg/kg) doses to rats for 14 consecutive days. Serum
proteins and hematological parameters remained unchan-
ged. Echocardiography assessments did not reveal changes
in hemodynamics or cardiac anatomy. These observations
were further confirmed by the examination of organ and
tissue histology. Our results demonstrate that CMICE-013
in its current formulation is safe in rodents. However,
additional studies in large animals using both acute and
subacute dosing regimens are required in order to claim
CMICE-013 safe for clinical applications.
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